Sofwave to Participate in the Jefferies Virtual Private MedTech Summit

Sofwave Medical Ltd, an emerging leader in energy-based non-invasive aesthetic medical devices, has announced its participation in the Jefferies Virtual Private MedTech Summit scheduled for October 1, 2025. Louis Scafuri, CEO, and Assaf Korner, CFO, will represent the company at this important industry event, where they are expected to discuss Sofwave's innovative technologies and market strategies.

Sofwave is known for its proprietary SUPERB™ (Synchronous Ultrasound Parallel Beam) technology, which has received FDA clearance for several cosmetic applications, including wrinkle reduction, lifting of facial features, and treatment of skin laxity in areas such as the upper arms and beneath the chin. This breakthrough technology not only addresses facial lines and wrinkles but also offers short-term improvements in the appearance of cellulite and the treatment of acne scars, making it a versatile solution in the aesthetic market.

The company’s Pure Impact™ module utilizes electrical muscle stimulation (EMS) technology, which is also FDA-cleared and focused on muscle toning. These advanced offerings allow medical professionals to provide patients with effective, safe, and user-friendly aesthetic treatments, setting Sofwave apart in a competitive landscape.

With ongoing developments and expanding applications, Sofwave Medical is poised to continue its growth trajectory in the aesthetic medical device market. The participation in the Jefferies Virtual Private MedTech Summit signifies the company's commitment to engaging with investors and industry stakeholders while showcasing its innovative solutions in non-invasive aesthetic treatments. For further information, interested parties can contact Sofwave at info@sofwave.com or reach out to investor relations representative Brian Ritchie at LifeSci Advisors.

Sofwave Medical Ltd (TASE: SOFW), a prominent player in the non-invasive aesthetic medical device sector, is poised to leverage significant visibility during the upcoming Jefferies Virtual Private MedTech Summit on October 1, 2025. This participation is crucial as it solidifies Sofwave's commitment to engaging with potential investors and stakeholders, particularly as it seeks to advance its innovative technology and expand its market reach.

The company's proprietary SUPERB™ technology has garnered attention in the aesthetic treatment market. FDA-cleared for wrinkle reduction, skin lifting, and cellulite treatment, Sofwave offers solutions that appeal to both practitioners and consumers. As aesthetic procedures continue to gain popularity, driven by increasing consumer desire for non-invasive options, Sofwave’s innovative offerings position it well for growth within this expanding market.

Investors should take note of several factors influencing Sofwave’s prospects. First, the wellness and beauty industry is rebounding post-pandemic, with patients increasingly seeking to enhance their appearance in a non-surgical manner. This trend bodes well for the continued adoption of Sofwave's solutions, potentially translating into higher revenue growth.

Additionally, the management team's engagement at relevant industry conferences, such as the Jefferies Summit, highlights their proactive approach to investor relations and market positioning. Listening to insights from CEO Louis Scafuri and CFO Assaf Korner could provide valuable guidance regarding future strategies and financial projections.

However, it is essential to consider market competition and regulatory dynamics within the MedTech space. Companies must continuously innovate and navigate compliance rigorously to maintain their positions.

Investors should monitor Sofwave closely post-summit for any updates or strategic announcements. With a robust product lineup and growing market demand, Sofwave Medical Ltd presents an intriguing opportunity in the evolving landscape of aesthetic medicine.